Literature DB >> 16531969

Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.

V Byrnes1, N Afdhal, T Challies, P E Greenstein.   

Abstract

Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity. Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta. We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16531969

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN： 1665-2681            Impact factor:   2.400


  6 in total

1.  Development of autoimmune hepatitis type 1 after pulsed methylprednisolone therapy for multiple sclerosis: a case report.

Authors:  Atsushi Takahashi; Yukiko Kanno; Yuta Takahashi; Natsumi Sakamoto; Kyoko Monoe; Hironobu Saito; Kazumichi Abe; Junko Yokokawa; Atsushi Irisawa; Hiromasa Ohira
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

2.  Autoimmune hepatitis induced by a single injection of interferon-β 1a in a patient with multiple sclerosis.

Authors:  Hiroki Yamaguchi; Kenji Sakai; Yoshinori Goto; Masahito Yamada
Journal:  J Neurol       Date:  2018-05-29       Impact factor: 4.849

3.  Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis.

Authors:  Kaarina Kowalec; Galen E B Wright; Britt I Drögemöller; Folefac Aminkeng; Amit P Bhavsar; Elaine Kingwell; Eric M Yoshida; Anthony Traboulsee; Ruth Ann Marrie; Marcelo Kremenchutzky; Trudy L Campbell; Pierre Duquette; Naga Chalasani; Mia Wadelius; Pär Hallberg; Zongqi Xia; Philip L De Jager; Joshua C Denny; Mary F Davis; Colin J D Ross; Helen Tremlett; Bruce C Carleton
Journal:  Nat Genet       Date:  2018-07-16       Impact factor: 38.330

4.  Delayed Liver Function Impairment Secondary to Interferon β-1a Use in Multiple Sclerosis.

Authors:  Ming-Feng Liao; Su-Chen Yen; Lin Chun-Yen; Lyu Rong-Kuo
Journal:  Case Rep Neurol       Date:  2013-07-20

5.  Presentation and outcomes with clinically apparent interferon beta hepatotoxicity.

Authors:  Robert J Fontana; Paul Hayashi; Herbert L Bonkovsky; David E Kleiner; Sweta Kochhar; Jiezhun Gu; Marwan Ghabril
Journal:  Dig Dis Sci       Date:  2013-02-02       Impact factor: 3.487

Review 6.  The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.

Authors:  Marco Biolato; Assunta Bianco; Matteo Lucchini; Antonio Gasbarrini; Massimiliano Mirabella; Antonio Grieco
Journal:  CNS Drugs       Date:  2021-07-28       Impact factor: 5.749
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.